See the DrugPatentWatch profile for Alglucosidase
What is alglucosidase alfa’s structure?
Alglucosidase alfa is a recombinant form of the human lysosomal enzyme acid alpha-glucosidase (GAA). Structurally, it is a glycoprotein produced in a mammalian expression system and designed to be taken up by cells via mannose-6-phosphate (M6P)-mediated trafficking to lysosomes. It is manufactured as an enzyme that includes both the amino-acid sequence of GAA and extensive N-linked carbohydrate (“glycan”) structures that carry the M6P signal required for lysosomal targeting.
Is it a single-chain protein or does it process into subunits?
Alglucosidase alfa is the enzymatic product of GAA. Like other lysosomal acid alpha-glucosidase preparations, it is delivered as an administered protein that functions as the active lysosomal enzyme after uptake into cells. The biologic’s effective structure in the body is determined by its glycosylation and how it folds and is processed in the lysosomal environment; these details are tied to the specific recombinant manufacturing and formulation, not to a simple, one-line “single-chain vs. two-chain” description.
What parts matter most for function?
For enzyme replacement, the structural features that most directly control function are:
- The GAA protein fold that positions the catalytic residues.
- The N-linked glycosylation pattern, including the M6P-containing glycans that drive lysosomal uptake.
Do different sources list different sequence lengths or glycosylation patterns?
Yes. The exact sequence length, the precise number and occupancy of glycosylation sites, and the detailed glycan composition can vary depending on the manufacturing process and the specific characterization data reported by the manufacturer in regulatory submissions. So “the structure” can mean the underlying amino-acid sequence (the same general enzyme), or the finalized, product-specific glycoform profile (which can differ between biologics lots, and is not fully captured by a generic schematic).
How does it compare structurally to other recombinant GAA products?
Alglucosidase alfa is one recombinant GAA biologic. Other recombinant GAA therapies can have differences in glycosylation or formulation because glycan processing depends on the expression system and manufacturing. Those glycosylation differences can affect lysosomal targeting efficiency, pharmacokinetics, and immunogenicity risk, even when the core enzyme is the same class of protein.
What details can be obtained from public records (e.g., patents, labels)?
Publicly accessible information usually focuses on:
- That it is recombinant human GAA (glycoprotein enzyme).
- That it contains glycans with lysosomal targeting capability (M6P).
- Product formulation and dosing, rather than full 3D coordinates or a complete glycan-by-glycan table.
If you tell me what you mean by “structure” (3D structure/coordinates, amino-acid sequence, domains, or glycosylation/M6P profile), I can narrow the answer to that specific structural level.